Small and mid-sized companies need the right partner.
Oncology remains the therapeutic area with the lowest success rate in clinical trials, underscoring the need for innovative approaches and a partner with deep experience in this fast-evolving, complex field.
As a specialized clinical solutions company primarily focusing on small to mid-sized biotechs, Allucent excels at designing and executing oncology and hematology clinical trials. Our expertise encompasses all development phases (I-IV), solid tumors, and hemato-oncology indications. We provide guidance and insight in optimized clinical strategy, choice of endpoints based on the mode of action or tumor biomarkers, patient selection, feasibility studies, up-to-data trend analysis, and results reporting.
A patient-centric approach is assured by clinical development informed by the special needs of oncology patients and supported by state-of-the-art enabling technologies, ranging from digital patient engagement strategies and eConsent to sensor technology and implementation. We are working at the forefront of oncology projects with cutting-edge treatments. Our network of medical and research experts can assist you with the right advice and insights. Our regulatory perspective is crucial to planning for study design, choice of endpoints, data strategy, and so much more and is provided as a key element of our strategic guidance for early planning and continuing through post-approval.
Oncology trials require oncology experts.
Supporting drug development for cancer treatment requires multilayered proficiency: in the science, in the different aspects of clinical research, and in the ability to understand the emotional and physical experience of trial participants. Every phase of a clinical trial is different. Beginning with Early Phase through Phase II, III, and beyond, Allucent has deep expertise in many indications and therapeutic classes and is confident in taking on the full complexity inherent in cancer research. Our extensive experience with full-service clinical trials and consulting projects has provided us with ample hands-on knowledge of a wide variety of indications.
- All comer (all solid tumors)
- Brain tumors (including GBM)
- Bladder cancer
- Breast cancer
- Cervical cancer
- Colorectal cancer
- Endometrial cancer
- Gastric cancer
- Head and neck cancer
- Liver cancer
- Lung cancer (including NSCLC)
- Neuroendocrine tumors
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
- Renal cancer
- All comer (all hemato-oncology)
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Chronic lymphocytic leukemia (CLL)
- Chronic myeloid leukemia (CML)
- Multiple myeloma
- Myelodysplastic syndromes
- Graft versus host disease
- Veno-occlusive disease
- Anticoagulant Reversal
- Autoimmune Hemolytic Anemia
- Blood Loss –
- Essential Thrombocythaemia
- Graft Versus Host Disease
- Hereditary Angioedema
- Hyperbilirubinemia (Genetic)
- Paroxysmal Nocturnal
- Sickle Cell Anemia
- Thrombotic Thrombocytopenic Purpura
- Antibodies (e.g., monoclonal, bi-specific, antibody drug conjugates (ACDs), checkpoint inhibitors)
- Cell based
- autologous & allogenic (e.g., dendritic cell (DC), natural killer (NK), T cell, stem cell)
- Hormonal (e.g., hormone receptor inhibitors, liposomal corticosteroids)
- Vaccines (e.g., bacterial vaccines, DNA vaccines, peptide vaccines, RNA vaccines, tumor-derived vaccines)
- Oncolytic viruses
- Radiolabeled compounds
- Antisense oligonucleotides
- miRNA compounds
- Chemotherapy (e.g., alkylating agents, anthracyclines, antimetabolites, anti-microtubule agents, taxanes, topoisomerase inhibitors)
- Inhibitors (e.g., angiogenesis inhibitors, HDAC inhibitors, integrin receptor antagonists, PARP inhibitors, protein kinase inhibitors, tyrosine kinase inhibitors (TKIs)
A commitment to delivering therapies that can deliver cures.
The Allucent team has many years of experience in traditional therapies, as well as the promising new therapeutic classes including molecularly targeted agents, immunotherapies, and cell and gene therapies. We are also well-versed in different combination therapies. We have substantial experience in anticancer vaccines, antibodies (monoclonal, bispecific, and ADCs); nanoparticle formulations; metabolic regulators; and modified chemotherapies for enhanced efficacy.
Our experts have deep knowledge of the novel trial designs emerging in modern practice, specifically in oncology and rare diseases. We have an impressive track record with advanced therapy medicinal products (ATMPs), medicines for human use based on genes, tissues, or cells. Allucent has collaborated on more than 60 research projects involving cell and gene therapy products and similar biologics for oncology, as well as several other therapeutic areas.
Beyond our specialization in Early Phase trials, we have substantial experience in conducting Late Phase, pivotal, and post-marketing trials, as well as compassionate use/early access programs. From clinical study design to clinical trial management, medical writing, clinical data management, and more, Allucent is the ideal partner.
Cancer research continues to improve available treatment options. Chemotherapy has been evolving; it is no longer used solely as a monotherapy modality but can also be part of a combination therapy modality. This approach allows for the use of optimal drug doses, resulting in decreased toxicity effects. It also reduces drug resistance and provides better outcomes for patients. Our clinical team has experience in chemotherapy combinations with targeted therapies and immunotherapies. In the last five years, our experts worked on over 20 studies ranging from Phases I to IV involving chemotherapy.
Cell and Gene Therapies
CAGT trials are logistically challenging, requiring highly adept, multidisciplinary expertise. Allucent understands the unique needs of the small and midsized biopharma companies that are often at the forefront of development in this exciting field. Our project teams have been involved in more than 40 CAGT studies and projects with both autologous and allogenic cell products. Besides trials that investigate natural killer (NK) cells, stem cells, dendritic cell, and T-cells, we have also worked on trials with oncolytic viruses.
Several types of cancers (e.g., breast and prostate) use hormones to grow. Altering the levels or activity of certain hormones can cause these cancers to cease growth and/or undergo cell death. We have performed studies with Aromatase inhibitors, selective estrogen receptor inhibitors, and synthetic gonadotropin releasing hormone agonists as single therapies but also as part of combination therapies.
Our experts have worked on more than 100 studies and projects in hematologic malignancies and solid tumors and are well-versed in the different immune-related tumor evaluation criteria such as irRC and iRECIST, as well as immune-related adverse events (irAE). We have in-depth knowledge and hands-on experience with IO drugs including antibodies, peptides, oligonucleotides, cell-based products, oncolytic viruses, and vaccines. This experience encompasses testing these drugs as combination therapy with classic chemotherapy and targeted therapy.
Our clinical team has worked with targeted therapies in Phase I to IV studies, encompassing complex adaptive trial designs and basket trials. We are experienced in mechanisms of action including the inhibition of angiogenesis, histone deacetylase (HDAC), integrin receptors, poly ADP ribose polymerase (PARP), growth factors, and the cell cycle, to name a few. Allucent has supported more than 115 studies and projects and worked with antibodies and small molecules such as protein kinase inhibitors. Our regulatory team has been involved in FDA approval of targeted therapies.
We are highly experienced in performing trials with radiolabeled proteins and Radium-223 in neuroendocrine tumors and prostate cancer. Our team of experts works in the United States and Europe across Phase I-IV trials and has supported the regulatory approval of new drug applications (NDAs) at the FDA and marketing authorization applications (MAAs) at the EMA of radiolabeled proteins.